Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,335.40up ₹25.40 (1.94%)BSE ₹1,335.40
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,310.00.
28 Oct: open ₹1,302.00, high ₹1,338.20, low ₹1,301.00
52-week range of traded prices to 28 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,11,463 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.81
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.87
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 28,39,06363.6% delivered
Dr. Reddy's Laboratories shareholding disclosures
153 filed, newest first. Page 3 of 4.
Aug 2016
Jul 2016
Apr 2016
Sep 2015
Jun 2015
May 2015
Apr 2015
Dec 2014
Nov 2014
Oct 2014
Sep 2014
Jul 2014
Jun 2014
May 2014
Jul 2013
Jun 2013
May 2013
Feb 2013
Jan 2013
Dec 2012
Oct 2012
Sep 2012
Jul 2012
Jun 2012
May 2012
12 May · Disclosure
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company in their meeting held on May 10, 2012 has granted 336,570 stock options, exercisable at par value of Rs.5/- under "Dr. Reddy's Employees Stock Option Scheme, 2002" and 58,840 stock options, exercisable at par value of Rs.5/- under "Dr. Reddy's Employees ADR Stock Option Scheme, 2007" to the employees of the Company.
Jan 2012
Nov 2011
May 2011
16 May · Disclosure
Dr. Reddy'S Laboratories Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on May 13, 2011, approved the grant of 9,600 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr.Reddy's Employees Stock Option Scheme, 2002" and also approved the grant of 7,200 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr.Reddy's Employees ADR Stock Option Scheme, 2007". Further the Nomination, Governance & Compensation Committee of the Board of Directors of the Company in their meeting held on May 12, 2011 approved the grant of 251,920 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr.Reddy's Employees Stock Option Scheme 2002" and also approved the grant of 48,860 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr.Reddy's Employees ADR Stock Option Scheme, 2007".
May 2010
10 May · Disclosure
Dr. Reddy'S Laboratories Limited has informed the Exchange that "The Board of Directors of the Company in their meeting held on May 06, 2010, approved the grant of 9,600 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr. Reddy's Employees Stock Option Scheme, 2002" and also approved the grant of 7,200 stock options, exercisable at par value of Rs.5/- to the Independent Directors of the Company under "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". Further the Compensation Committee of the Board of Directors of the Company in their meeting held on May 06, 2010 approved the grant of 275,070 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr. Reddy's Employees Stock Option Scheme, 2002" and also approved the grant of 51,460 stock options, exercisable at par value of Rs.5/- to the employees of the Company under "Dr. Reddy's Employees ADR Stock Option Scheme, 2007".